4 stories mentioning JBIO
Every FINWIRES story that references JBIO, newest first.
Jade Biosciences (JBIO) has an average rating of buy and mean price target of $45.89, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Jade Biosciences (JBIO) has an average rating of buy and mean price target of $38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $18.59, Change: $-2.45, Percent Change: -11.64%
Jade Biosciences (JBIO) said late Tuesday the first participant has been dosed in a first-in-human phase 1 clinical trial of JADE201, an investigational, half-life extended, afucosylated monoclonal antibody.The first-in-human trial is a placebo-controlled study assessing single ascending doses of JADE201 in participants with rheumatoid arthritis, according to a statement.Jade said interim phase 1 data in rheumatoid arthritis anticipated in 2027 are expected to inform indication prioritization across potential autoimmune indications supported by B cell activating factor receptor biology.
Healthcare stocks were advancing premarket Tuesday, with the iShares Biotechnology ETF (IBB) 0.4% higher and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2%.Eli Lilly (LLY) has agreed to acquire Curevo, LimmaTech Biologics, and Vaccine Company in deals worth up to nearly $3.83 billion in total, expanding its presence in infectious disease prevention, the company said. Shares of Eli Lilly were up more than 1% pre-bell.Natera (NTRA) stock was up more than 2% after the company said it has upgraded its Panorama non-invasive prenatal test using SNP-informed deep sequencing to improve accuracy in samples with low fetal fraction.Jade Biosciences (JBIO) has dosed the first participant in its phase 2 trial of experimental therapy, JADE101, for immunoglobulin A nephropathy, or IgAN, the drugmaker said. Shares of Jade Biosciences were up more than 5% premarket.